On October 18, 2024, Prof. Sergio Bernardini, Secretary of International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) visited Zybio. By visiting Zybio's instrument and reagent R&D, raw material R&D, reference system department, production base and exhibition hall in headquarters, he appreciated Zybio's capability in scientific innovation based on an in-depth understanding of Zybio's efforts and achievements in scientific and technological innovation. 

Prof. Sergio Bernardini, (MD, PhD), is a full professor of Clinical Biochemistry and Clinical Molecular Biology at the Department of Internal Medicine of The University of Rome Tor Vergata, one of the top public universities in Rome, Italy, and the head physician of the Clinical Molecular Biology Unit at the Tor Vergata University Hospital, with rich experience in theoretical research and clinical practice.

The visit started from Zybio's R&D base, where Prof. Sergio Bernardini experienced Zybio's R&D environment of “Courage to Innovate, Commitment to Truth, Dedication to Perfection”, exchanged views with Zybio on the current R&D technology platform and innovative R&D technology planning, and put forward a lot of valuable suggestions. During the visit, Prof. Sergio Bernardini highly appreciated Zybio's development of raw materials and reference system. 

Raw materials of excellent quality are the basis of reliable performance of reagents, and are the key part of the IVD industry chain, the quality of which affects the entire diagnostic and healthcare cycle. After more than ten years of research and development of diagnostic raw materials, Zybio has built its own core technology platform for core raw materials development for in vitro diagnostic reagents and research on key diagnostic technologies. Currently, Zybio has been the first Chinese developer of a number of raw material products, and reserves advanced technology for raw material platforms and transformed production capacity, which greatly reduces the demand for high-grade diagnostic antibody raw materials (monoclonal antibodies such as IgG4, MxA, Lp-plA2 and CG), diagnostic enzymes (molecular enzymes and biochemical enzymes), and key diagnostic chemical materials (magnetic beads, latex microspheres) and break through the bottleneck of raw material technologies.

In addition, in order to ensure the reliability of the measurement results of IVD products, Zybio has set up the Reference System Department, which is responsible for the traceability and quality evaluation of the products, and has established traceability laboratories for clinical chemistry, CLIA, hematology, urinalysis and coagulation testing, to continually improve and upgrade the traceability system of the diagnostic products, and to ensure the accuracy of the product test results. Currently, Zybio has established traceability for more than 200 products, covering clinical chemistry, CLIA, hematology, coagulation, urinalysis and POCT, etc. It has realized the goal of product traceability to the highest level available, and the traceability and accuracy of the products are in line with international standards, which meets the user's high demand for the accuracy of product measurements. 

Afterwards, Prof. Sergio Bernardini visited Zybio's digital showroom and gained a deeper understanding of the company's development history, technological innovations and achievements in the field of in vitro diagnostics since its establishment in 2008, and gained a more intuitive understanding of Zybio's technological strength and future development prospects. Prof. Sergio Bernardini had a discussion with us at the headquarters of Zybio. In the course of the meeting, both sides had an in-depth discussion on the latest progress of innovative technology, product development and academic research in the field of laboratory testing. Prof. Sergio Bernardini and Zybio team had an in-depth exchange on the excellent cooperation between IFCC and enterprises, and jointly explored how to push forward the progress of laboratory testing through academic cooperation and technological innovation to meet the growing demand for healthcare.

In addition, the two sides shared their outlook on possible future cooperation, aiming to jointly facilitate the breakthrough and application of laboratory testing technology through strengthening industry-academia-research cooperation, and to build a bridge for the in-depth integration of academia and industry. This exchange and cooperation will not only help accelerate the transformation of scientific and technological achievements, but also contribute to the enhancement of public health services and the protection of the health and well-being of the general public.